Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a Chinese pharmaceutical company, has announced that it has obtained clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 chemical drug HSK44459. This phosphodiesterase 4B (PDE4B) inhibitor is now set to be evaluated for its efficacy in treating interstitial lung disease (ILD).
ILD is characterized as a group of diseases that primarily affect the lung’s interstitial spaces, alveoli, and bronchioles, potentially progressing to diffuse pulmonary fibrosis. This can lead to significant structural damage in lung tissue, widespread dysfunction, and in severe cases, respiratory failure and death. HSK44459 is designed to exhibit anti-inflammatory and anti-fibrotic properties by inhibiting the release of inflammatory factors and the proliferation and activation of fibroblasts. As a selective PDE4B inhibitor, HSK44459 is anticipated to mitigate adverse reactions in the gastrointestinal tract and central nervous system that are commonly associated with traditional, non-selective PDE4 inhibitors, while maintaining its anti-inflammatory benefits. Currently, no drugs with the same target are available in the global market. Preclinical data suggest that HSK44459 has a clear target profile, precise efficacy, and an excellent safety profile.- Flcube.com
